Phase 1/2 Trial to Evaluate Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B Cirrhosis After First-Line Therapy
Latest Information Update: 08 Aug 2024
At a glance
- Drugs Cabozantinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 06 Aug 2024 Status changed from active, no longer recruiting to discontinued.
- 02 Nov 2023 Status changed from recruiting to active, no longer recruiting.
- 30 Aug 2023 Planned End Date changed from 1 Jul 2026 to 1 Dec 2026.